Click here for our latest publication on measuring cognition as part of routine care
self-administered
clinically-validated
easily integrated
Our vision is to enable transformational improvement in patient care by providing medical devices for collecting highly standardized clinical data and patient-reported outcomes, in any medical or home setting.
Qr8 Health’s platform technology incorporates standardized, validated digital tests for the measurement of neurological and motor function along with patient reported outcomes that are self-administered on a mobile tablet device and easily integrated into electronic health records.
Our platform technology has future potential in the detection and treatment of:
The first example of our platform in clinical use is the Multiple Sclerosis Performance Test (MSPT), an iPad-based assessment tool designed to objectively quantify major motor, visual, and cognitive symptoms for patients with multiple sclerosis. The MSPT is administered during routine clinical visits and test results are automatically posted to the patient’s electronic health record.
MSPT is current being utilized by the Cleveland Clinical Mellen Center for Multiple Sclerosis and in over 50 multiple sclerosis centers globally.
Both cognitive and physical function can be negatively impacted by many neurological disorders and are important to assess early and regularly in order to provide a more personalized care plan. Neuro At Home™ is an FDA registered digital application* that assesses domains most commonly affected by these diseases and can be conveniently completed by the patient outside of the clinic setting.
*Currently available as an investigational tool for use in all patient groups
Information processing speed and memory are often negatively affected in many neurological disorders and are important to identify early. Cognition Snapshot™ is an FDA registered digital application that quickly evaluates processing speed, spatial & verbal memory for use in all patient groups.
Information processing speed can be impacted by neurological disorders such as Alzheimer’s disease and Parkinson’s disease. Identification is important as processing speed impairment can potentially be modified with cognitive training and future therapeutic intervention.
David Blum, Wendy Gable & Jane Rhodes, PhD
Rao, S., Galioto, R., Sokolowski et al. Eur J Neurol 2020 Feb 3
Gabrielle Macaron, Brandon P. Moss, Hong Li et al. Neurol Clin Pract Sept 2019, 10.1212
Rao S., Losinski G., Mourany L., et al. | Mult Scier 2017 Dec;23(14):1929-1937